Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    What's Hot

    A stunning’ 4% yearly rise in R&D share has emerging biopharma dominating the pipeline

    March 31, 2023

    Under pressure, biotech and pharma grapple with how to take climate action

    March 30, 2023

    Antibody-patent row could have far-reaching impact on biotech

    March 29, 2023
    Facebook Twitter Instagram
    Your Biotech
    • Bio Technology

      A stunning’ 4% yearly rise in R&D share has emerging biopharma dominating the pipeline

      March 31, 2023

      Under pressure, biotech and pharma grapple with how to take climate action

      March 30, 2023

      Antibody-patent row could have far-reaching impact on biotech

      March 29, 2023

      Alan Kohler: Australia’s biotech sector has suddenly got much bigger

      March 28, 2023

      Why Do So Few Biotech Startups Want To Be The Next Big Pharma Company?

      March 27, 2023
    • Pharmaceutical

      Pharma company owner duped of ₹1.1 crore

      November 11, 2022

      Novavax cuts full-year revenue forecast again amid weak demand

      November 10, 2022

      Aurobindo units recall products in US market for manufacturing issues

      November 9, 2022

      AASLD 2022 | Ascentage Pharma Releases Phase I Results of IAP Antagonist APG-1387 in an Oral Report Showing Potential for Functionally Curing CHB

      November 8, 2022

      Trade Spotlight | What should you do with Amara Raja, Sun Pharma Advanced Research, Poly Medicure on Monday?

      November 7, 2022
    Your Biotech
    Home»Bio Technology»Revolutionizing Biotechnology: Scientists Create Supercharged Bacteria With Immunity to Viral Infections
    Bio Technology

    Revolutionizing Biotechnology: Scientists Create Supercharged Bacteria With Immunity to Viral Infections

    yourbiotechBy yourbiotechMarch 17, 2023Updated:March 17, 2023No Comments5 Mins Read
    Facebook Twitter Pinterest LinkedIn Tumblr WhatsApp VKontakte Email
    Share
    Facebook Twitter LinkedIn Pinterest Email

    In a step forward for genetic engineering and synthetic biology, researchers have modified a strain of Escherichia coli bacteria to be immune to natural viral infections while also minimizing the potential for the bacteria or their modified genes to escape into the wild. The work promises to reduce the threats of viral contamination when harnessing bacteria to produce medicines such as insulin as well as other useful substances, such as biofuels. Currently, viruses that infect vats of bacteria can halt production, compromise drug safety, and cost millions of dollars.

    We believe we have developed the first technology to design an organism that can’t be infected by any known virus,” said the study’s first author, Akos Nyerges, research fellow in genetics in the lab of George Church in the Blavatnik Institute at Harvard Medical School and the Wyss Institute for Biologically Inspired Engineering.

    “We can’t say it’s fully virus-resistant, but so far, based on extensive laboratory experiments and computational analysis, we haven’t found a virus that can break it,” Nyerges said.

    The work also provides the first built-in safety measure that prevents modified genetic material from being incorporated into natural cells, he said.

    The authors said their work suggests a general method for making any organism immune to viruses and preventing gene flow into and out of genetically modified organisms (GMOs). Such biocontainment strategies are of increasing interest as groups explore the safe deployment of GMOs for growing crops, reducing disease spread, generating biofuels, and removing pollutants from open environments.

    a group from the University of Cambridge thought they’d made an E. coli strain immune to viruses. But then Nyerges teamed up with research fellow Siân Owen and graduate student Eleanor Rand in the lab of co-author Michael Baym, assistant professor of biomedical informatics at the Blavatnik Institute at HMS. When they sampled local sites rife with E. coli, including chicken sheds, rat nests, sewage, and the Muddy River down the street from the HMS campus, they discovered viruses that could still infect the modified bacteria.

    Discovering that the bacteria weren’t fully virus-resistant “was a bummer,” Nyerges said.

    The initial method involved genetically reprogramming E. coli to make all their life-sustaining proteins from 61 sets of genetic building blocks, or codons, instead of the naturally occurring 64. The idea was that viruses wouldn’t be able to hijack the cells because they couldn’t replicate without the missing codons.

    Phages Infect Bacterial Cell

    An illustration of viruses called phages infecting a bacterial cell. Researchers have developed a modified strain of Escherichia coli bacteria that is resistant to natural viral infections and has a low risk of escaping into the environment. This breakthrough in genetic engineering and synthetic biology is expected to decrease the risk of viral contamination in the production of medicines and other substances, such as biofuels. Currently, viral infections in bacteria can cause a halt in production, endanger drug safety, and result in high financial costs. Credit: Behnoush Hajian

    Researchers create virus-resistant, safely restrained E. coli for medical, and industrial applications.

    In a step forward for genetic engineering and synthetic biology, researchers have modified a strain of Escherichia coli bacteria to be immune to natural viral infections while also minimizing the potential for the bacteria or their modified genes to escape into the wild.

    The work promises to reduce the threats of viral contamination when harnessing bacteria to produce medicines such as insulin as well as other useful substances, such as biofuels. Currently, viruses that infect vats of bacteria can halt production, compromise drug safety, and cost millions of dollars.

    “We believe we have developed the first technology to design an organism that can’t be infected by any known virus,” said the study’s first author, Akos Nyerges, research fellow in genetics in the lab of George Church in the Blavatnik Institute at Harvard Medical School and the Wyss Institute for Biologically Inspired Engineering.

    “We can’t say it’s fully virus-resistant, but so far, based on extensive laboratory experiments and computational analysis, we haven’t found a virus that can break it,” Nyerges said.

    The work also provides the first built-in safety measure that prevents modified genetic material from being incorporated into natural cells, he said.

    The authors said their work suggests a general method for making any organism immune to viruses and preventing gene flow into and out of genetically modified organisms (GMOs). Such biocontainment strategies are of increasing interest as groups explore the safe deployment of GMOs for growing crops, reducing disease spread, generating biofuels, and removing pollutants from open environments.

    Building on what came before

    The findings build on earlier efforts by genetic engineers to achieve a helpful, safe, virus-resistant bacterium.

    In 2022, a group from the University of Cambridge thought they’d made an E. coli strain immune to viruses. But then Nyerges teamed up with research fellow Siân Owen and graduate student Eleanor Rand in the lab of co-author Michael Baym, assistant professor of biomedical informatics at the Blavatnik Institute at HMS. When they sampled local sites rife with E. coli, including chicken sheds, rat nests, sewage, and the Muddy River down the street from the HMS campus, they discovered viruses that could still infect the modified bacteria.

    Discovering that the bacteria weren’t fully virus-resistant “was a bummer,” Nyerges said.

    The initial method involved genetically reprogramming E. coli to make all their life-sustaining proteins from 61 sets of genetic building blocks, or codons, instead of the naturally occurring 64. The idea was that viruses wouldn’t be able to hijack the cells because they couldn’t replicate without the missing codons. The HMS team, however, figured out that deleting codons wasn’t enough. Some viruses were bringing in their own equipment to get around the missing pieces.

    Share. Facebook Twitter Pinterest LinkedIn Tumblr WhatsApp Email
    Previous ArticlePfizer is buying cancer biotech in one of the biggest pharma deals in history
    Next Article AMGEN AND NSG BIOLABS ANNOUNCE ALBATROZ THERAPEUTICS AS THE WINNER OF THE FIRST AMGEN GOLDEN TICKET IN SINGAPORE
    yourbiotech
    • Website

    Related Posts

    A stunning’ 4% yearly rise in R&D share has emerging biopharma dominating the pipeline

    March 31, 2023

    Under pressure, biotech and pharma grapple with how to take climate action

    March 30, 2023

    Antibody-patent row could have far-reaching impact on biotech

    March 29, 2023

    Alan Kohler: Australia’s biotech sector has suddenly got much bigger

    March 28, 2023

    Leave A Reply Cancel Reply

    Our Picks

    Subscribe to Updates

    Get the latest creative news from SmartMag about art & design.

    About Us
    About Us

    We provide a wide range of customized, integrated B2B and B2C digital marketing services solutions that are ideal for your business.

    We're accepting new partnerships right now.

    Email Us: info@yourmartech.com
    Contact: +1-530-518-1420

    Our Brands
    • Your Martech
    • Your HR Tech
    • Your Fin Tech
    • Your Revenue
    • Your Info Tech
    • Your POS Tech
    • Your Health Tech
    SUBSCRIBE NOW
    Loading
    LinkedIn
    • Privacy Policy
    © 2022 Vigarbiz Inc. Designed by Vigarbiz Media

    Type above and press Enter to search. Press Esc to cancel.